Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and functionally contributes to increase tumor aggressiveness

ABSTRACT: RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and functionally contributes to increase tumor aggressiveness

PROVIDER: PRJNA769401 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16233400.fastq.gz	Fastqsanger.gz
	SRR16233401.fastq.gz	Fastqsanger.gz
	SRR16233402.fastq.gz	Fastqsanger.gz
	SRR16233403.fastq.gz	Fastqsanger.gz
	SRR16233404.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 30

Similar Datasets

RANK is an independent biomarker of poor prognosis in estrogen receptor-negative breast cancer and functionally contributes to increase tumor aggressiveness

Project description:Analyses of genes expression in estrogen receptor negative, RANK positive, breast cancer orthoxenografts after in vivo treatment (4 weeks) with RANKL , RANK-Fc or denosumab.

2023-01-19 | GSE185513 | GEO

Rank pathway activation attenuates mammary tumorigenesis by inducing senescence

Project description:Rank overexpression attenuates mammary tumorigenesis by inducing senescence in mammary epithelial cells but enhances tumor aggressiveness by increasing stemness.

2022-02-24 | GSE139675 | GEO

CD45- sorted tumor cells from RANK+/+ and RANK-/- MMTV_PYMT late carcinomas

Project description:Transcriptional profile of either RANK+/+ or RANK-/- MMTV-PyMT late carcinomas, orthotopically injected in syngeneic RANK+/+ mice. Once host mice developed tumors, CD45- tumor cells were sorted by flow cytometry in order to compare changes on tumor gene expression caused by the absence of RANK protein.

2020-10-06 | GSE119464 | GEO

CD45- sorted tumor cells from RANK+/+ and RANK-/- MMTV_PYMT late carcinomas

Project description:CD45- sorted tumor cells from RANK+/+ and RANK-/- MMTV_PYMT late carcinomas

| PRJNA489283 | ENA

Transcriptome analysis of RANK-positive and RANK-negative luminal progenitor subpopulations in the human breast

Project description:RANK-positive and RANK-negative luminal progenitor cells were isolated by FACS from histologically normal human breast tissue from wild-type human donors. RNA-seq gene expression profiling was used to find differentially expressed genes between the RANK-positive and RANK-negative cell populations.

2016-06-20 | GSE71203 | GEO

Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

Project description:Multiple myeloma immunoglobulin lambda translocations portend poor prognosis

| PRJNA499054 | ENA

ECT2 associated to PRICKLE1 are poor-prognosis markers in triple-negative breast cancer

Project description:Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype and the lack of specific signature makes difficult the development of targeted therapeutic strategy. We previously found that PRICKLE1, an evolutionary conserved protein acting as a regulator of vertebrate development, is upregulated in TNBC. Proteomic approaches allowed us to decipher the protein complex associated to PRICKLE1 in TNBC. Within that complex, we identified a large subset of proteins involved in the regulation of Rho-GTPase family members. We build a metagene with regulators of small G-protein activity and we found that this metagene is overexpressed in TNBC and is a poor prognosis marker. We analyzed the combination of the metagene expression and PRICKLE1 expression and identified that combined expression of ECT2 and PRICKLE1 provides a worst prognosis than PRICKLE1 expression alone in TNBC. ECT2 is a GEF for Rac1 and we showed that PRICKLE1 regulate the enzymatic activity of ECT2. Finally, we also observed that Ect2 and Prickle1 are functionally connected during evolution since both act synergistically to coordinate cellular movement during vertebrate gastrulation. Our results demonstrate the pivotal role of PRICKLE1 in TNBC and build the path for development of targeted therapeutic strategies to heal TNBC patients.

2019-10-15 | PXD011253 | Pride

RANK-Fc treatment in MMTV-PyMT late carcinoma

Project description:Transcriptional profile of MMTV-PyMT late carcinomas after adjuvant or neoadjuvant treatment with RANK-Fc (receptor activator of NF-kB) cells isolated from one single MMTV-PyMT carcinoma were orthotopically injected in syngeneic WT mice, which were randomized 1:1 for neoadjuvant RANK-Fc or mock treatment (passage 1) for 4 weeks. Cells isolated from both treatment arms were pooled and injected into the fat pad of FvB recipients (passage 2) in limiting dilutions (mimicking occult disease) and again randomized 1:1 for additional RANK-Fc (adjuvant) or mock treatment

2016-12-19 | GSE66085 | GEO

Distinct gene expression profile between ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis groups

Project description:Cancer tissue specimens from ARID1Ahigh and good prognosis and ARID1Alow and poor prognosis of patients with advanced gastric cancer were extracted and analyzed.

2018-02-06 | GSE110078 | GEO

Gene expression profiles of Ccl21a+ and Rank+ E17 thymic epithelial cells

Project description:Gene expression profiles of Ccl21a+ and Rank+ E17 thymic epithelial cells (TECs) were compared using Ccl21a-tdTomato-KI Rank-Venus-Tg mice

2023-11-09 | GSE239913 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data